Department of Psychiatry and Psychotherapy, Faculty of Health and Medical Sciences , University Medical Center Mainz , D-55131 Mainz , Germany.
Department of Drug Design and Pharmacology , University of Copenhagen , DK-2100 Copenhagen , Denmark.
J Med Chem. 2018 Mar 8;61(5):1951-1968. doi: 10.1021/acs.jmedchem.7b01484. Epub 2018 Feb 26.
δ-Selective compounds 1 and 2 (DS1, compound 22; DS2, compound 16) were introduced as functionally selective modulators of δ-containing GABA type A receptors (GABAR). In our hands, [H]EBOB-binding experiments with recombinant GABAR and compound 22 showed no proof of δ-selectivity, although there was a minimally higher preference for the α4β3δ and α6β2/3δ receptors with respect to potency. In order to delineate the structural determinants of δ preferences, we synthesized 25 derivatives of DS1 and DS2, and investigated their structure-activity relationships (SAR). Four of our derivatives showed selectivity for α6β3δ receptors (29, 38, 39, and 41). For all of them, the major factors that distinguished them from compound 22 were variations at the para-positions of their benzamide groups. However, two compounds (29 and 39), when tested in the presence of GABA, revealed effects at several additional GABAR. The newly synthesized compounds will still serve as useful tools to investigate α6β3δ receptors.
δ-选择性化合物 1 和 2(DS1,化合物 22;DS2,化合物 16)被引入作为含有 δ 的 GABA 型 A 受体(GABAR)的功能选择性调节剂。在我们手中,用重组 GABAR 和化合物 22 进行 [H]EBOB 结合实验没有证明 δ 选择性,尽管相对于效力,它们对 α4β3δ 和 α6β2/3δ 受体有轻微的更高偏好。为了描绘 δ 偏好的结构决定因素,我们合成了 DS1 和 DS2 的 25 种衍生物,并研究了它们的结构-活性关系(SAR)。我们的四个衍生物对 α6β3δ 受体具有选择性(29、38、39 和 41)。对于它们中的所有化合物,与化合物 22 区分开来的主要因素是苯甲酰胺基团的对位的变化。然而,两种化合物(29 和 39)在 GABA 存在下进行测试时,在几个其他 GABAR 中显示出作用。新合成的化合物仍将作为研究 α6β3δ 受体的有用工具。